A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast

February 7, 2017 updated by: Binghe Xu, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
To study the epidemiological trends and characteristics for advanced breast cancer patients, to analyze these trends and report the results

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

In this study, the investigators conducted a hospital-based retrospective clinical study, recruiting female advanced breast cancer patients from 14 tertiary hospitals at 7 classic geographic regions, to study the clinical epidemiologic characteristics of advanced breast cancer and the current standard of clinical diagnosis and treatment in order to provide references for standardized treatment therapy, and to improve the quality of life and prolong survival time.

To study the epidemiological trends and characteristics for advanced BC patients, to analyze these trends and report the results. To learn about the current treatment therapy for advanced BC patients in different areas in China.To provide references for standardized treatment therapy, to improve the quality of patients' life and to prolong the survival time for the advanced BC patients.To assess the different treatment therapies for advanced BC with consideration of economic cost-effectiveness

Study Type

Observational

Enrollment (Anticipated)

4200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
      • Beijing, China
        • Not yet recruiting
        • The 307th Hospital of Military Medical Sciences
        • Contact:
          • Zefei Jiang
      • Chengdu, China
        • Not yet recruiting
        • Sichuan Cancer Hospital and Institute
        • Contact:
          • Hui Li
      • Chongqing, China
        • Not yet recruiting
        • The First Affliated Hospital of Chongqing Medical University
        • Contact:
          • Hongyuan Li
      • Fuzhou, China
        • Not yet recruiting
        • FuZhou General Hospital of National Miltary Command
        • Contact:
          • Xuenong Ouyang
      • Guangzhou, China
        • Not yet recruiting
        • Sun Yat-sen University Cancer Center
        • Contact:
          • Shuseng Wang
      • Harbin, China
        • Not yet recruiting
        • Harbin Medical University Cancer Hospital
      • Henan, China
        • Not yet recruiting
        • Henan Cancer Hospital
      • Hunan, China
        • Not yet recruiting
        • Hunan Cancer Hospital
      • Jiangsu, China
        • Not yet recruiting
        • Jiangsu Provinces hospital
        • Contact:
          • Yongmei Yin
      • Kunming, China
        • Not yet recruiting
        • Tumor Hospital of Yunnan Province
      • Liaoning, China
        • Not yet recruiting
        • Liaoning Cancer Hospital, Zhejiang Cancer Hospital
      • Ningxia, China
        • Recruiting
        • General Hospital of Ningxia Medical University
        • Contact:
          • Xinlan Liu
      • Shanghai, China
        • Not yet recruiting
        • Fudan University Shanghai Cancer Center
      • Shenyang, China
        • Not yet recruiting
        • The First Hospital of China Medical University
      • Tianjin, China
        • Not yet recruiting
        • Tianjin Medical University Cancer Institute & Hospital
      • Wuhan, China
        • Not yet recruiting
        • Wuhan Union Hospital
        • Contact:
          • Tao Huang
      • Xi'an, China
        • Not yet recruiting
        • The First Hospital of Xi'an Jiaotong University
        • Contact:
          • Jianjun He
      • Xinjiang, China
        • Not yet recruiting
        • Xinjiang Medical University Cancer Hospital
        • Contact:
          • Shune Yang
      • Zhengzhou, China
        • Not yet recruiting
        • Fujian provincial Cancer Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

A total of 21 hospitals were selected in this study. The investigators recruited 4200 advanced BC cases, who were first diagnosed with advanced BC from January 1st, 2012 to December 31st, 2014 from these hospitals.

Description

Inclusion Criteria:

  • diagnosed as advanced breast cancer during Jan1st,2012-Dec31st,2014
  • complete with surgical pathology data, auxiliary treatment, there is a clear recurrence, transfer time, place, transfer of recurrence after treatment, and curative effect evaluation details.In any age, ethnic group cases.

Exclusion Criteria:

  • no available medical record

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Survival status at 3 years
Time Frame: 3 years
percentage of patients still alive at 3 years
3 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PFS
Time Frame: 3 years
Progression-free survival of first line therapy
3 years
Survival status at 5 years
Time Frame: 3 years
percentage of patients still alive at 5 years
3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Investigators

  • Principal Investigator: Youlin Qiao, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2016

Primary Completion (Anticipated)

April 1, 2017

Study Completion (Anticipated)

December 1, 2017

Study Registration Dates

First Submitted

November 29, 2016

First Submitted That Met QC Criteria

February 7, 2017

First Posted (Estimate)

February 9, 2017

Study Record Updates

Last Update Posted (Estimate)

February 9, 2017

Last Update Submitted That Met QC Criteria

February 7, 2017

Last Verified

February 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • CH-BC-045

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Advanced Breast Cancer

Clinical Trials on standard therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe